Klin Padiatr 2014; 226 - P_25
DOI: 10.1055/s-0034-1371140

Treatment of Children and Adolescents with Hodgkin's Lymphoma According to Recommendations of DAL/GPOH-HD Group (Preliminary Results)

N Myakova 1, A Rudneva 1, N Denisov 1, Y Abugova 1, Y Diakonova 1, D Konovalov 1, A Nechesnyuk 1, D Rogozhin 1, N Smirnova 1, E Samochatova 1, M Belogurova 1, 2, O Streneva 1, 2, 3, N Ponomareva 1, 2, 3, 4, R Parkhomenko 1, 2, 3, 4, 5, O Ryskal' 1, 2, 3, 4, 5, 6
  • 1Federal Center for Pediatric Hematology/Oncology/Immunology, Oncohematology, Moscow, Russian Federation
  • 231 Hospital, Pediatric Oncology, St-Petersburg, Russian Federation
  • 3Regional Children's Hospital, Ekaterinburg, Russian Federation
  • 4Russian Children's Hospital, Oncohematology, Moscow, Russian Federation
  • 5Federal Scientific Center of Roentgenoradiology, Moscow, Russian Federation
  • 6Regional Children's Hospital, Perm', Russian Federation

Since 2006 in some Russian hospitals patients with Hodgkin's lymphoma (HL) are treated according to recommendations of DAL/GPOH-HD group. All first line patients get two cycles of OE*PA. Patients in TG-1 do not receive further chemotherapy. Patients in TG-2 and -3 receive either COPDAC for two or four cycles respectively. After chemotherapy all patients receive reduced involved field (RIF) radiotherapy with a total dose of 20 Gy to the initially involved lymph node areas. In our conditions PET-scans were used uncommonly and only to access tumor response.

There were 122 patients, who began therapy from 16.01.06 to 25.01.12; M:F = 61:61; aged 3.0 – 20.5 years, median 13.9 y. Median follow-up was 2.5 y. There were 10 pts (8%) in the 1st risk group (RG), 38(31%) and 74(61%) in the 2nd and 3rd, respectively. In the whole group there were 6 non-responders (4.9%), 6 pts relapsed (4.9%), one got secondary tumor – thyroid carcinoma (0.8%), one died due to tumor progression (0.8%), 109 (89.3%) are in continuous complete remission. 7-years probability of EFS for all pts = 0.77 ± 0.09, for RG1 = 0.86 ± 013, for RG2 = 0.93 ± 0.05, for RG3 = 0.72 ± 0.11. No severe toxic events were seen during chemotherapy. Quality of life needs further evaluation.

Conclusions: the protocol is feasible and effective for pediatric patients with HL. We need to standardize diagnostic tools and control of irradiation quality in all hospitals in order to improve treatment results, especially in RG3 pts.